GERMANTOWN, Md., Dec 21 (Bernama-GLOBE NEWSWIRE) --
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing
novel treatments for nervous system diseases, today announced that Xi
Chen, Ph.D., has been appointed to its Board of Directors, effective
immediately. Dr. Chen was appointed by Tianjin to replace Zhang Zhuo as
the director appointee of the Series A Convertible Preferred Stock.
“It
is our pleasure to welcome Dr. Chen to the Board of Directors,” said
Rich Daly, Chairman and CEO. “Dr. Chen comes to us with years of
therapeutic development and administrative expertise, and the
contributions and guidance that he has to offer will be highly valuable
to the future of the Company.”
Dr. Chen has served as the
Assistant General Manager of Manufacture, Equipment, and Administration
at Tianjin Kinnovata Pharmaceutical since 2014. He also served as the
Deputy Director of the Marketing Department at Tianjin Pharmaceutical
Holdings since 2012. Previously, Dr. Chen was the Executive Vice General
Manager of Tianjin Lights Medical Device Co., and a Research Associate,
Lab Manager at the University of Ottawa, and Anesthesiologist at
Tianjin Union Hospital.
Dr. Chen. holds a PhD in Enterprises
Management, a Master’s Degree in Molecular Biology from University of
Ottawa, and a Clinical Bachelor’s Degree from Tianjin Medical
University.
About Neuralstem
Neuralstem is a
clinical-stage biopharmaceutical company developing novel treatments for
nervous system diseases of high unmet medical need. NSI-189 is a small
molecule in clinical development for major depressive disorder (MDD)
and in preclinical development for Angelman syndrome,
irradiation-induced cognitive impairment, Type 1 and Type 2 diabetes,
and stroke. NSI-566 is a stem cell therapy being tested for treatment
of paralysis in stroke, chronic spinal cord injury (cSCI) and
Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified portfolio
of product candidates is based on its proprietary neural stem cell
technology.
Cautionary Statement Regarding Forward Looking Information
This
news release contains “forward-looking statements” made pursuant to the
“safe harbor” provisions of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements relate to future, not past,
events and may often be identified by words such as “expect,”
“anticipate,” “intend,” “plan,” “believe,” “seek” or “will.”
Forward-looking statements by their nature address matters that are, to
different degrees, uncertain. Specific risks and uncertainties that
could cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of our
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements. Additional
information on potential factors that could affect our results and other
risks and uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the year
ended December 31, 2016, and Form 10-Q for the three and nine months
ended September 30, 2017, filed with the Securities and Exchange
Commission (SEC), and in other reports filed with the SEC. We do not
assume any obligation to update any forward-looking statements.
Contact:
Kimberly Minarovich
Argot Partners (Investor Relations)
212-600-1902
kimberly@argotpartners.com
SOURCE : Neuralstem, Inc.
No comments:
Post a Comment